ReviewMayo Clinic proceedings2017
Microbiome at the Frontier of Personalized Medicine.
Review in Mayo Clinic proceedings, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
115 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gut Microbiota-microRNA Interactions and Obesity Pathophysiology: A Systematic Review of Integrated Studies.International journal of molecular sciences · 2024Pooled it
- Diet- and sex-related changes of gut microbiota composition and functional profiles after 4 months of weight loss intervention.European journal of nutrition · 2021Trial
- Beyond bacilli: integrating the microbiome into the TB research agenda.Gut microbes · 2026Review
- The Gut Microbiota-Epilepsy Axis: Bibliometric Trends, Mechanistic Insights, and Microbiota-Targeted Next-Generation Therapeutic Opportunities.Molecular neurobiology · 2026Review
- Toward Precision Cardiac Rehabilitation: Current Limitations and Future Opportunities of Omics and Artificial Intelligence.Sports medicine (Auckland, N.Z.) · 2026Review
- Targeting tumor-associated bacteria in digestive system cancers: carcinogenic mechanisms and nano-regulate platform design.Journal of nanobiotechnology · 2026Review
- Therapeutic Management of Probiotics and Prebiotic Products to Modulate Gut Microbiome by Healthcare Services.Microorganisms · 2026Review
- 3D Bioprinting of an Oral Colon Delivery System for Precision Bacteriotherapy.Pharmaceutics · 2026Article
- Microbiome modulating remedies for chronic diseases: a review of current interventions and future directions.Inflammopharmacology · 2026Review
- Metaproteomics uncovers the functional capacity of a soil microbiome.Scientific reports · 2026Article
- Precision Microbiome Modulation: Exploring Lactobacillus spp. as A Targeted Strategy for Type 2 Diabetes Management.Current nutrition reports · 2026Review
- Article
- The impact of gut microbiota on leukemia and prospects for novel therapies.Infectious medicine · 2026Review
- The relationship between gut microbiota and neurodegenerative diseases: a genetic and epigenetic perspective.Metabolic brain disease · 2026Review
- Age-driven dysbiosis: gut microbiota in the pathogenesis and treatment of aging disorders.Biogerontology · 2026Review
- From Womb to World: Unravelling the Microbiota's Impact on Health and Disease.International journal of microbiology · 2026Review
- A realistic simulation-based benchmark of microbiome normalization in sample stratification and taxa-level analysis.Frontiers in bioinformatics · 2026Article
- Integrated gut microbiota and metabolomics analysis of the effect of pomegranate peel powder on intestinal inflammation in broilers induced by high non-starch polysaccharides.Frontiers in immunology · 2026Article
- Navigating gastrointestinal challenges in genetic myopathies: Diagnostic insights and future directions.World journal of methodology · 2025Article
- HAFMMDA: HIN2vec-Based Attentional Factorization Machines for Predicting Microbe-Drug Associations.Interdisciplinary sciences, computational life sciences · 2025Article
55 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The genomic revolution promises to transform our approach to treat patients by individualizing treatments, reducing adverse events, and decreasing health care costs. The early advances using this have been realized primarily by optimizing preventive and therapeutic approaches in cancer using human genome sequencing. The ability to characterize the microbiome, which includes all the microbes that reside within and upon us and all their genetic elements, using next-generation sequencing allows us to now incorporate this important contributor to human disease into developing new preventive and therapeutic strategies. In this review we highlight the importance of the microbiome in all aspects of human disease, including pathogenesis, phenotype, prognosis, and response to treatment, as well as their role as diagnostic and therapeutic biomarkers. We provide a role for next-generation sequencing in both precise microbial identification of infectious diseases and characterization of microbial communities and their function. Taken together, the microbiome is emerging as an integral part of precision medicine approach as it not only contributes to interindividual variability in all aspects of a disease but also represents a potentially modifiable factor that is amenable to targeting by therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.